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Abstract
Aims/hypothesis The list of validated type 2 diabetes
susceptibility variants has recently been expanded from
three to 19. The variants identified are common and have
low penetrance in the general population. The aim of the
study is to investigate the combined effect of the 19 variants
by applying receiver operating characteristics (ROC) to
demonstrate the discriminatory value between glucose-
tolerant individuals and type 2 diabetes patients in a cross-
sectional population of Danes.
Methods The 19 variants were genotyped in three study
populations: the population-based Inter99 study; the ADDI-
TION study; and additional type 2 diabetic patients and
glucose-tolerant individuals. The case–control studies in-
volved 4,093 type 2 diabetic patients and 5,302 glucose-
tolerant individuals.
Results Single-variant analyses demonstrated allelic odds
ratios ranging from 1.04 (95% CI 0.98–1.11) to 1.33 (95%
CI 1.22–1.45). When combining the 19 variants, subgroups
with extreme risk profiles showed a threefold difference in
the risk of type 2 diabetes (lower 10% carriers with ≤15 risk
alleles vs upper 10% carriers with ≥22 risk alleles, OR 2.93
(95% CI 2.38–3.62, p=1.6×10−25). We calculated the area
under a ROC curve to estimate the discrimination rate
between glucose-tolerant individuals and type 2 diabetes
patients based on the 19 variants. We found an area under
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the ROC curve of 0.60. Two-way gene–gene interaction
showed few nominal interaction effects.
Conclusions/interpretation Combined analysis of the 19
validated variants enables detection of subgroups at
substantially increased risk of type 2 diabetes; however,
the discrimination between glucose-tolerant and type 2
diabetes individuals is still too inaccurate to achieve clinical
value.
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Abbreviations
GWA Genome-wide association
MAF Minor allele frequency
ROC Receiver operating characteristic
SNP Single-nucleotide polymorphism
Introduction
Type 2 diabetes is a rapidly growing public health problem
and although environmental factors are of major importance,
genetic risk factors also predispose to the disease. Until
recently, only three gene loci, PPARG [1], KCNJ11 [2, 3] and
TCF7L2 [4], had convincingly shown replicated association
with type 2 diabetes. However, within the last 2 years
results of genome-wide association studies (GWA) have
revolutionised the field of research and identified 14 new
susceptibility type 2 diabetes variants [5–15]. Together with
WFS1 [16] and TCF2 (also known as HNF1B) [17, 18],
identified by a candidate gene approach, the total number of
validated type 2 diabetes susceptibility loci now reaches 19.
All identified alleles associated with type 2 diabetes risk are
common (minor allele frequency [MAF]>5%) and have a
low penetrance (OR<1.5) in the general population. Little is
known about the molecular mechanisms by which these
variants increase diabetes risk; however, physiological studies
have demonstrated that the majority may mediate their
pathogenic effect through an abnormal beta cell function,
which seems to be the case for CDKAL1, SLC30A8, HHEX,
CDKN2A, IGF2BP2, TCF7L2, KCNJ11, WFS1, CDC123,
JAZF1, MTNR1B and TSPAN8 [3, 8, 14, 19–23]. As for the
remaining susceptibility variants, a predisposing effect
through obesity affecting an increase in fat accumulation has
been demonstrated for variation inFTO [24, 25] and variation
in PPARG has shown a potentially pathogenic effect on type
2 diabetes through an impairment of insulin sensitivity [26].
An important question is, to what extent do the combined
effect of these variants predict which individuals are at risk
of developing type 2 diabetes. Indeed, if the discrimination is
successful, the prospect of prediction and application of
genotype-based early and individualised prevention and
treatment strategies for type 2 diabetes would be of major
clinical importance.
The issue of combining the known available type 2
diabetes susceptibility variants has been addressed before in
case–control settings. Before the release of GWA studies,
Weedon et al. [27] demonstrated that the combined effect of
three common genetic variants only moderately enabled
discrimination between type 2 diabetes patients and glucose-
tolerant individuals (AUC of the receiver operating charac-
teristics [ROC] 0.58). With the recent release of GWA
studies and thus the expansion of the number of validated
type 2 diabetes susceptibility variants, three studies have
investigated the combined effect of 17 independent loci on
type 2 diabetes risk and although subgroups of carriers of
several risk alleles were considered to be at high risk of
developing type 2 diabetes, the overall conclusion pointed
towards a low discriminative ability between cases and
controls assessed by the AUC of an ROC curve [28–30].
Also, two prospective studies estimated the predictive value
of 16 and 18 type 2 diabetes susceptibility variants,
respectively. The studies demonstrated that even though the
discriminatory power of genetic testing is limited, it increases
with duration of follow up [31, 32], suggesting that even
genetic risk factors with moderate effects may, on a life-long
basis, contribute considerably to diabetes risk.
Recently, two new type 2 diabetes candidate genes were
discovered. A Japanese study reported the result of a genome-
wide scan of 268,068 single-nucleotide polymorphisms
(SNPs) and identified KCNQ1 as a type 2 diabetes
susceptibility gene [11, 12]. The rs2237895 variant—
located in the intronic region of KCNQ1—showed an OR
1.23 (95% CI 1.18–1.29, p<1×10−16). Additionally, three
recent papers reported that variants in the MTNR1B locus
strongly associate with type 2 diabetes risk and a meta-
analysis of MTNR1B rs10830963 demonstrated OR 1.09
(95% CI 1.05–1.12, p=3.3×10−7) [13–15].
Here we present an updated study evaluating the
combined effect of 19 validated type 2 diabetes suscepti-
bility variants; it includes the newly discovered KCNQ1
and MTNR1B variants that in the Danish population
showed to be the fifth and second strongest type 2
diabetes-associated variants, respectively. By applying
ROC curves in a large sample of Danes we demonstrate
how well the 19 variants discriminate between glucose-
tolerant individuals and type 2 diabetes patients alone and
in combination with known type 2 diabetes risk factors
such as BMI, age and sex. In addition, we investigate
whether the combined effect from the variants is explained
additively or whether a synergistic effect on diabetes risk
(two-way gene–gene interaction) exists between the
variants.
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Methods
Study population The 19 type 2 diabetes susceptibility
variants were genotyped in 9,395 Danes involving: (1) the
population-based Inter99 sample (ClinicalTrials.gov
NCT00289237) of middle-aged individuals sampled at the
Research Centre for Prevention and Health (n=4,928) [33];
(2) type 2 diabetes patients and glucose-tolerant individuals
sampled through the outpatient clinic at Steno Diabetes
Center (n=2,107 and n=734, respectively); and (3) screen-
detected type 2 diabetes patients from the Danish ADDITION
screening cohort (ClinicalTrials.gov NCT00237549) sampled
through Department of General Practice at University of
Aarhus (n=1,626) [34]. Study group 1 and glucose-tolerant
individuals from study group 2 underwent a standard 75 g
oral glucose tolerance test. Informed written consent was
obtained from all participants before participation. The study
was approved by the Ethical Committee of Copenhagen
and Aarhus Counties and was in accordance with the
principles of the Helsinki Declaration. Glucose-tolerant
individuals and type 2 diabetes patients were defined
according to World Health Organization 1999 criteria [35].
Individuals with type 2 diabetes had increased BMI and age
(mean BMI 30.6±5.5 kg/m2, mean age 60±10 years)
compared with glucose-tolerant individuals (mean BMI
25.6±4.0 kg/m2, mean age 47±9 years).
Statistical analysis For each variant we estimated the
multiplicative effect on type 2 diabetes risk as well as the
two-way gene–gene interaction by applying logistic regres-
sion with adjustment for sex and age. The two-way interaction
was performed by comparing one model including only the
main effect (SNP) with an alternative model including a
SNP–SNP interaction variable in addition to the main effect.
The covariate for each SNP was denoted as the number of
disease alleles (i.e. coded as 0, 1 or 2 according to the number
of risk alleles) and the pair-wise interaction as the product of
the pairs of SNPs (i.e. multiplicative interaction).
When estimating the combined effect of the 19 suscepti-
bility SNPs, each risk allele was defined as the allele
associated with increased risk of type 2 diabetes in
previous studies [5–18], hence each individual is assigned
a risk score ranging from zero to 38. For each risk score the
numbers of glucose-tolerant individuals and type 2 diabetic
patients were calculated. Fisher’s exact test was applied to
test whether the distribution of glucose-tolerant individuals
and type 2 diabetes patients was different for subgroups
with multiple risk scores and few risk scores.
Receiver operating characteristics We estimated the dis-
criminatory power between glucose-tolerant individuals and
type 2 diabetes patients of the 19 susceptibility variants by
applying ROC. We used logistic regression including all
variants coded as 0, 1 or 2 according to the number of risk
alleles. In order to cross-validate the results, bootstrapping
(n=50) was applied. Cross-validation works by fitting the
same model in different bootstraps (subsets of the original
data). The remaining subsets (out-of-bag data) are used for
the selectivity of the fitted model. For each ROC, an area
under the curve is used as a measure of the predictive
power of the method. Each ROC curve in the present paper
consists of the result of all bootstraps, themeanROC estimated
from the bootstrap samples by taking the mean of the bootstrap
sample at each 1–selectivity point and the apparent ROC curve
which are estimated from the entire dataset. All analyses were
performed using RGui version 2.7.0, applying the per package
(http://www.r-project.org, accessed 1 May 2008).
Results
The clinical characteristics of all participants in the three
study samples are reported in Electronic supplementary
material (ESM) Table 1. We estimated the association of
each of the 19 validated variants on type 2 diabetes risk by
applying a multiplicative genetic model. Results of the risk
of susceptibility variants adjusted for sex, age and BMI can
be found in ESM Fig. 1. However, here we focus on results
adjusted for sex and age as BMI is an effect modifier
compared with sex and age, which are considered con-
founders (Fig. 1).
The minor alleles of CDKN2A, THADA, JAZF1, HHEX
and SLC30A8 variants were associated with a decreased
risk of developing type 2 diabetes, whereas the minor
alleles of TCF7L2, CDKAL1, KCNQ1, FTO, KCNJ11,
TSPAN8, CDC123, MTNR1B, and IGF2BP2 variants were
associated with an increased risk of type 2 diabetes. As for
the remaining loci, no association was observed although
the directions were consistent with previous reports. The
OR for each individual variant ranged from 1.04 (95% CI
0.98–1.11; NOTCH2; i.e. no association) to 1.33 (95% CI
1.22–1.45) for TCF7L2, so far the largest risk effect of all
common type 2 diabetes loci. As for the result of the single-
variant analysis all data have been published previously [8,
12, 13, 21–23, 36–38].
The combined effect of the 19 variants was estimated by
calculating the percentage of glucose-tolerant individuals
and type 2 diabetic patients stratified according to the
number of risk alleles (Fig. 2). We demonstrate that, on
average, type 2 diabetic patients carry more risk alleles and
thus the curve is shifted right compared with the curve of
glucose-tolerant individuals (Fig. 2). By stratifying the
number of risk alleles into quartiles we estimated OR 2.13
(95 % CI 1.85–2.47, p=4.91×10−26) between the lowest
quartile (number of risk alleles ≤16, n=1,404) and the
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uppermost quartile (number of risk alleles ≥20, n=1,927).
In addition, if we stratify the individuals into subgroups of
extreme risk allele profiles by comparing the lower 10%
(carriers of eight to 15 risk alleles) with the upper 10%
(carriers of 22 to 29 risk alleles) we estimate OR 2.93 (95%
CI 2.38–3.62, p ¼ 1:6 1025).
The discriminatory value of a genetic test based on the
19 type 2 diabetes susceptibility variants was calculated as
the area under the ROC, which is a graphical plot of the
sensitivity vs (1−specificity). The area under the ROC was
estimated to 0.60 (Fig. 3a). We also tested whether the 19
susceptibility variants added to the discriminatory power
when accounting for known type 2 diabetes risk factors
such as BMI, age and sex (Fig. 3b). A model that includes
only BMI, age and sex has an AUC of 0.92 and after
applying the 19 susceptibility variants an AUC of 0.93 was
achieved (Fig. 3c).
Finally we estimated the two-way interaction between
each combination of the 19 variants (171 combinations)
(ESM Table 1) and the result demonstrated few, probably
spurious, associations (p<0.05). As none of the associa-
tions was significant after Bonferroni correction we believe
that an additive model between each variant is acceptable.
Additionally, we calculated the AUC under an ROC curve
in which a model including all variants (additive) is
compared with a model including a two-way interaction
term in addition to the variants (interaction). The results
showed that if interaction is included an AUC of 0.56 is
reached, which indicates reduced discriminatory value
(ESM Fig. 2).
Discussion
In our analyses, in which we applied ROC to demonstrate
the discriminatory value between 5,302 glucose-tolerant
individuals and 4,093 type 2 diabetes patients of the
combined effect of 19 validated type 2 diabetes suscepti-
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Fig. 2 The percentage of
glucose-tolerant individuals
(white bars) and type 2 diabetes
patients (grey bars) stratified
according to number of risk
alleles of the 19 validated type 2
diabetes variants. The OR is
calculated using Fisher’s exact
test as number of glucose-
tolerant individuals and type 2
diabetes patients carrying ≤16
risk alleles (the lowest quartile)
vs the number of glucose-
tolerant individuals and type 2
diabetes patients carrying ≥20
risk alleles (uppermost quartile).
†OR 2.13, p=4.0×10−26
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Fig. 1 ORs and 95% CIs of the 19 validated variants for type 2 diabetes
using a genetic multiplicative model adjusted for sex and age. The risk
alleles of the 19 variants are defined as the alleles associated with type 2
diabetes in accordance with the literature [5–18]. The 19 variants may
exert their diabetogenic effects through: beta cell dysfunction (solid
line); altered BMI (dotted line); changes in insulin sensitivity (dashed/
dotted line); and unknown mechanisms (dashed line)
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bility variants, we were able to identify subgroups with
substantial increases in risk of type 2 diabetes. For instance,
in a subgroup of individuals carrying more than 22 risk
alleles we estimated an odds ratio of 2.93 (95% CI 2.38–
3.62, p=1.6×10−25) compared with individuals carrying
fewer than 15 risk alleles. However, when evaluating the
general ability to discriminate between glucose-tolerant
individuals and type 2 diabetes patients, assessed by the
area under an ROC curve, we estimated an AUC of 0.60.
The ROC analyses in the same study samples of the
corresponding discriminatory value of conventional risk
factors such as BMI, age and sex resulted in an AUC of
0.92 and when the 19 susceptibility variants were included
an AUC of 0.93. Thus, although tremendous progress in
finding type 2 diabetes susceptibility genes has recently
taken place, the discriminatory value of the common genetic
variations is still too limited to be of clinical importance. For
illustration, if we screen a sample of individuals for the 19
type 2 diabetes susceptibility genes and we want to detect
80% of the type 2 diabetic patients, we have to account for
the fact that 70% of the healthy individuals are misclassified
as type 2 diabetic patients (Fig. 3a).
Our results are in line with the conclusions from recent
cross-sectional and longitudinal studies assessing the
combined impact of several risk alleles on type 2 diabetes
risk [27–32]. In the recent prospective study by Lyssenko et
al., it was demonstrated that the addition of 16 type 2
diabetes susceptibility variants to clinical risk factors
improved the prediction of future type 2 diabetes assessed
by the area under an ROC curve from 0.74 to 0.75 [31].
A major limitation in the current and previous comparable
cross-sectional studies is the fact that case–control designs
are used that comprise approximately equal numbers of
glucose-tolerant individuals and type 2 diabetic patients. As
a result, the discriminatory value is overestimated as the
prevalence rate at the population level constitutes approxi-
mately 6% compared with a case–control design which often
includes equal numbers of cases and controls. Another
limitation when calculating the OR between carriers of
multiple risk alleles and few risk alleles is the fact that each
risk allele is assigned the same effect. This limitation,
however, is overcome when calculating ROC curves where
each SNP is assigned an individual effect size. Also, when
we run the ROC analyses with age included we introduce an
overestimation of the discriminatory value as the majority of
the type 2 diabetic patients in most studies are older than the
glucose-tolerant individuals.
Gene–gene interaction, the fact that one gene variant
masks or enhances the effect of another variant significantly
affecting a disease association, has been discussed as one of
the promising tools to explain the variation in type 2 diabetes
risk. A recent study suggested a significant interaction
between variants in IGF2BP2 and LOC38776, SLC30A8
and HHEX on risk of type 2 diabetes [28]; these variants are
all known to mediate the pathogenic effect through an
abnormal beta cell function. Indeed we also attempted to
replicate such findings by estimating the two-way interac-
tion between the 19 variants. The result demonstrated
sporadic nominally significant interactions which are most
likely to be due to type 1 errors and are not consistent with
any of the previous findings [28]. A possible explanation
may be a lack of statistical power, as the 19 susceptibility
variants investigated here confer a modestly increased risk
of type 2 diabetes. Based on 95% confidence interval
estimates of the effect size, we can in the current study
exclude a gene–gene interaction OR above 2.6 between two
variants on type 2 diabetes risk (data not shown). The
suggestion that only additivity between the examined type
2 diabetes variants appears to exist is also emphasised in
ESM Fig. 2 where the discrimination value is reduced when
including possible two-way genetic interaction terms. The
results seem to be in line with previous studies [29, 30].
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Fig. 3 ROC curves for the discrimination between glucose-tolerant
individuals and type 2 diabetes patients. The grey shadow represents
ROC curves obtained in the process of bootstrap cross-validation
(n=50). The mean of the bootstrapping ROC curves is presented as a
thin solid line. The dotted line represents the apparent ROC curve
estimated from the original data. a The mean AUC of the bootstrap
samples (thick solid line) based on the 19 type 2 diabetes
susceptibility variants (AUC 0.60). b The mean AUC of the bootstrap
samples when including conventional type 2 diabetes risk factors
(BMI, age and sex) (AUC 0.92). c The mean AUC of the bootstrap
when including the 19 susceptibility variants and clinical type 2
diabetes risk factors (BMI, age and sex) (AUC 0.93)
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In the present paper we have investigated common
variants with a low penetrance in the general population
and demonstrated limited success in the discrimination of
glucose-tolerant individuals and type 2 diabetes patients
based on the genetic profile. Janssens et al. [39] investigated
the usefulness of genomic profiling in the general popula-
tion by simulating a population of 1 million individuals
carrying 40 genotypes under different scenarios. The study
demonstrated that common variants with low penetrance
have little predictive power as we also show in the present
paper. In contrast, it has been proposed that accumulation
of rare variants with a mildly deleterious effect may
substantially increase the relative risk at the individual
level [40]. Indeed, with the next generation of sequencing
technologies enabling gene-specific re-sequencing of the
entire human genome, rare variants may be identified that
in combination may contribute substantially to the risk of
type 2 diabetes. Such results together with the known
common susceptibility variants may increase the discrimi-
native value of genetic risk factors and push the limit
towards a threshold acceptable for clinical utility.
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